CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
46.16
-1.10 (-2.32%)
Nov 21, 2024, 2:32 PM EST - Market open
CRISPR Therapeutics AG Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | -239.59 | -153.61 | -650.18 | 377.66 | -348.87 | 66.86 | Upgrade
|
| Depreciation & Amortization | 19.32 | 19.84 | 24.17 | 17.95 | 9.18 | 4.73 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 2.5 | - | - | - | - | Upgrade
|
| Loss (Gain) on Equity Investments | - | - | - | - | - | 5.47 | Upgrade
|
| Stock-Based Compensation | 83.04 | 81.03 | 97.95 | 102.39 | 66.02 | 44.06 | Upgrade
|
| Other Operating Activities | -28.23 | -16.55 | 12.47 | 14.11 | 1.86 | -16 | Upgrade
|
| Change in Accounts Receivable | - | -200 | 0.31 | -0.16 | -0.05 | -0.01 | Upgrade
|
| Change in Accounts Payable | -28.62 | -20.25 | 5.16 | 37.51 | 25.75 | 5.03 | Upgrade
|
| Change in Unearned Revenue | -2.52 | 5.79 | -1.01 | -0.78 | 1.38 | -45.15 | Upgrade
|
| Change in Other Net Operating Assets | 7.79 | 20.87 | 15.39 | -9.71 | 6.36 | -8.3 | Upgrade
|
| Operating Cash Flow | -188.82 | -260.38 | -495.74 | 538.97 | -238.37 | 56.68 | Upgrade
|
| Capital Expenditures | -2.39 | -9.47 | -37.19 | -81.71 | -18.36 | -6.68 | Upgrade
|
| Cash Acquisitions | - | - | - | - | - | 8.01 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -2.5 | - | - | - | - | Upgrade
|
| Investment in Securities | -465.38 | 386.62 | -221.47 | -953.73 | -522.81 | - | Upgrade
|
| Investing Cash Flow | -467.76 | 374.65 | -258.66 | -1,035 | -541.17 | 1.33 | Upgrade
|
| Issuance of Common Stock | 354.05 | 62.66 | 38.59 | 250.95 | 1,016 | 430.98 | Upgrade
|
| Financing Cash Flow | 354.05 | 62.66 | 38.59 | 250.95 | 1,016 | 430.98 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.13 | 0.07 | -0.08 | -0.01 | 0.04 | 0.02 | Upgrade
|
| Miscellaneous Cash Flow Adjustments | -0 | -0 | - | - | - | - | Upgrade
|
| Net Cash Flow | -302.41 | 177.01 | -715.88 | -245.52 | 236.66 | 489 | Upgrade
|
| Free Cash Flow | -191.2 | -269.85 | -532.93 | 457.27 | -256.72 | 49.99 | Upgrade
|
| Free Cash Flow Margin | -94.27% | -72.69% | -44484.89% | 49.98% | -35705.70% | 17.26% | Upgrade
|
| Free Cash Flow Per Share | -2.31 | -3.41 | -6.85 | 5.69 | -3.89 | 0.88 | Upgrade
|
| Levered Free Cash Flow | -118.57 | -238.97 | -337.58 | 284.82 | -112.91 | 58.15 | Upgrade
|
| Unlevered Free Cash Flow | -118.57 | -238.97 | -337.58 | 284.82 | -112.91 | 58.15 | Upgrade
|
| Change in Net Working Capital | 10.79 | 188.78 | 1.78 | -12.73 | -51.77 | 13.16 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.